このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

PHOTOFINISH: 感染した糖尿病性足潰瘍の治療のための通常のケア (UC) と UC 単独に加えて、システム VULNOFAST® Plus/VULNOLIGHT® の有効性と安全性を評価するための臨床研究 (PHOTOFINISH)

糖尿病患者の感染した足潰瘍の治療のための通常のケアと通常の単独ケアに加えて、VULNOFAST® Plus / VULNOLIGHT® システムの局所適用の有効性と安全性を評価する無作為化非盲検多施設共同臨床研究 (PHOTOFINISH) )

The aim of this randomised, open-label, multicentre clinical trial is to evaluate the superiority of the treatment which foresees the addition of the system VULNOFAST® plus / VULNOLIGHT® to the Usual Care, versus the treatment with Usual Care alone, for the healing of chronic diabetic foot ulcer. VULNOFAST® plus is a sterile solution used in combination with a red light source VULNOLIGHT®. Usual Care is defined as procedures to apply to the foot ulcer, carried out in the order in which they are listed in the protocol.

調査の概要

状態

完了

条件

介入・治療

詳細な説明

This study evaluates the superiority of the treatment which foresees the addition of the system VULNOFAST® plus / VULNOLIGHT® to the Usual Care, versus the treatment with Usual Care alone, for the healing of chronic diabetic foot ulcer.

Eligible patients are randomised in a 1:1 ratio to receive Usual Care and the system VULNOFAST® plus / VULNOLIGHT®, or Usual Care alone according the following scheme:

  • Arm A: Usual Care alone: 2 times a week (4 treatment weeks, 8 treatments).
  • Arm B: system VULNOFAST® plus / VULNOLIGHT® in addition to Usual Care: both treatments 2 times a week (4 treatment weeks, 8 treatments of Usual Care and 8 treatments of system VULNOFAST® plus / VULNOLIGHT®).

The Treatment period will be followed by a Follow up period: the study will last up to 57 days for each patient, including the screening period. Thirteen study visits are planned starting from the screening and including Treatment and Follow up periods.

All patients enrolled in this study:

  • are administered with amoxicillin and clavulanic acid treatment (as background antibiotic therapy) from Visit 1 until receipt of the antibiogram. Upon receipt of the antibiogram, the Investigator decides whether or not to continue the background therapy or to treat the patient with a different antibiotic treatment, according the clinical practice in the site.
  • use an appropriate off-loading system from Visit 1 to Visit 12

The primary objective is to assess clinical improvement after 2 weeks of study treatment by evaluation of the following primary endpoint:

- proportion of patients who had total bacterial load ≤ 1000 CFU/ml at Visit 5 (Visit 5 is the first visit of 3rd week of treatment), measured by punch biopsy.

The key secondary objective is also to assess clinical improvement after 4 weeks of study treatment reflected by the key secondary endpoint:

- proportion of patients who had a reduction of the target ulcer area ≥ 40% from the baseline (Visit 1) to the first follow-up visit (Visit 9) after 4 weeks of study treatment, assessed by MolecuLight i:X medical device.

Further secondary objectives are evaluated in the study, and a pharmacoeconomic analysis is foreseen.

研究の種類

介入

入学 (実際)

78

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Arezzo、イタリア
        • U.O.C. Diabetologia e Malattie Metaboliche, Ospedale San Donato
      • Florence、イタリア
        • Unit Piede Diabetico, SODc Diabetologia e Malattie del Metabolismo, Azienda Ospedaliero-Universitaria Careggi
      • Palermo、イタリア
        • U.O. Malattie Endocrine del Ricambio e della Nutrizione, Azienda Ospedaliero-Universitaria Policlinico Giaccone
      • Perugia、イタリア
        • Dipartimento di Endocrinologia e Malattie Metaboliche, Centro Piede Diabetico, Ospedale S. Maria della Misericordia
      • Pistoia、イタリア
        • SOS Diabetologia, Presidio Ospedaliero San Jacopo
    • Genova
      • Genova、Genova、イタリア、16149
        • Centro di Assistenza Vulnologica, Ospedale Villa Scassi
    • Milano
      • Milan、Milano、イタリア、20138
        • Unità di Diabetologia, Endocrinologia e Malattie Metaboliche, IRCSS Centro Cardiologico Monzino

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Main Inclusion Criteria:

  • Able and willing to give voluntary written informed consent. The ICF, must be signed before any study-related procedures and/or assessments are performed.
  • Outpatients or inpatients (male and female) of any ethnic origin, aged 18 years or over, diagnosed with type 1 or type 2 diabetes mellitus.
  • Glycaemic control confirmed by a glycated haemoglobin (HbA1c) levels ≤10% (86 mmol/mol), evaluated in the 3 months before enrolment or at Visit 1.
  • Fasting plasma glucose (FPG) less than 300 mg/dl.
  • A chronic diabetic foot ulcer (DFU) below the malleolus, with an area ≥ 2 and ≤ 40 cm2 and with a maximum diameter/length ≤ 10 cm measured by MolecuLight i:X medical device [note: chronic wound is defined as a wound that, after the normal clinical practice, does not start healing within 4 weeks or does not heal within 8 weeks].
  • A diabetic foot wound with a depth equal or higher to grade 2 according to the category "Depth/tissue loss" of PEDIS, but not involving bone, diagnosed by clinical examination.
  • Presence of infected foot ulcer of grade 2 according to the category "Infection" of PEDIS, diagnosed by clinical examination.
  • Able to take oral medications.
  • Patients must be willing and able to comply with the protocol and study procedures.

Main Exclusion Criteria:

  • Patients unable to give written informed consent.
  • Females who are pregnant or lactating.
  • Females who are of child bearing potential and not taking adequate contraceptive precautions are excluded from the trial. Females of child bearing potential taking acceptable contraceptive precautions can be included.
  • Participation in any other clinical trial or currently receiving any other investigational product(s) within 30 days prior to Visit 1.
  • Ankle brachial systolic blood pressure index < 0.5 (Winsor Index) in the infected limb.
  • Ulcer probe to bone positive.
  • Any surgery planned during the study period (from ICF signature to last planned follow-up visit).
  • Clinical diagnosis of peripheral vascular disease (PVD) requiring percutaneous or surgical revascularization.
  • Transcutaneous oximetry (TcPo2) measurement < 30 mmHg.
  • Use of any antibiotics (local or systemic) within 48h before Visit 1.
  • Patient for whom punch biopsy is contraindicated.
  • Patients that cannot take amoxicillin and clavulanic acid (background antibiotic therapy) at the dosage stated in the protocol and according to the current Summary of Product Characteristics (SPC).
  • Patients that cannot be treated with topical antiseptic containing Iodopovidone and/or with iodopovidone impregnated gauze according to the contraindication available in the current Summary of Product Characteristics (SPC).

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:アーム A: 通常のケアのみ

Usual Care is defined as the following procedures to apply to the foot ulcer, carried out in the order in which they are listed:

Sharp debridement (the debridement will be performed only if non-vital tissue is present), Mild washing of the whole ulcer with physiological solution, Treatment with topical antiseptic containing Iodopovidone, Covering with iodopovidone impregnated gauze while the ulcer is clinically infected (PEDIS ≥ 2) [If, during the study, PEDIS is < 2, the ulcer will be covered with nonadherent paraffin gauze].

Treatment 2 times a week (4 treatment weeks, 8 treatments).

実験的:アーム B: システム VULNOFAST® plus / VULNOLIGHT® 通常のケアに加えて

System VULNOFAST® plus / VULNOLIGHT®: VULNOFAST® plus sterile solution, in combination with a red light source VULNOLIGHT®. VULNOFAST® plus and VULNOLIGHT® will be used in accordance with their Instructions for Use (IFU) and User Manual.

Treatments 2 times a week (4 treatment weeks, 8 treatments of Usual Care and 8 treatments of system VULNOFAST® plus / VULNOLIGHT®).

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
To assess the ulcer after 2 weeks of study treatment by evaluation of the following primary endpoint:
時間枠:Visit 5 is the first visit of 3rd week of treatment.

Proportion of patients who had total bacterial load ≤ 1000 CFU/ml at Visit 5, measured by punch biopsy.

Visit 5 is the first visit of 3rd week of treatment.

二次結果の測定

結果測定
メジャーの説明
時間枠
The key secondary objective is to evaluate the ulcer after 4 weeks of study treatment by evaluation of the following endpoint:
時間枠:Visit 9 is after 4 weeks of study treatment

Proportion of patients who had a change of the target ulcer area ≥ 40% from the baseline (Visit 1) to the first follow-up visit (Visit 9) after 4 weeks of study treatment, assessed by MolecuLight i:X medical device.

Visit 9 is after 4 weeks of study treatment

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年9月14日

一次修了 (実際)

2026年4月7日

研究の完了 (実際)

2026年4月7日

試験登録日

最初に提出

2022年11月4日

QC基準を満たした最初の提出物

2022年11月4日

最初の投稿 (実際)

2022年11月14日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月3日

QC基準を満たした最後の更新が送信されました

2026年11月2日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • MOLT-2019-01

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。